GeoVax Labs Inc. (GOVX)
| Bid | 0.97 |
| Market Cap | 13.66M |
| Revenue (ttm) | 3.95M |
| Net Income (ttm) | -24.99M |
| EPS (ttm) | -4.82 |
| PE Ratio (ttm) | -0.2 |
| Forward PE | -0.99 |
| Analyst | Buy |
| Ask | 0.99 |
| Volume | 245,524 |
| Avg. Volume (20D) | 611,711 |
| Open | 1.03 |
| Previous Close | 1.01 |
| Day's Range | 0.94 - 1.03 |
| 52-Week Range | 0.73 - 11.18 |
| Beta | 3.71 |
About GOVX
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, ch...
Analyst Forecast
According to 6 analyst ratings, the average rating for GOVX stock is "Buy." The 12-month stock price forecast is $14.5, which is an increase of 1368.65% from the latest price.
Stock Forecasts
2 weeks ago · https://thefly.com
GeoVax Labs price target lowered to $14 from $18 at D. Boral CapitalD. Boral Capital lowered the firm's price target on GeoVax Labs to $14 from $18 and keeps a Buy rating on the shares. GeoVax has encountered a significant challenge following the termination of its BA...
